EUVIMEDEUVIMED entdecken
Open Access

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma

Ana Amélia de Souza, Albina Altemani, Ney Soares de Araujo, Lucas Novaes Texeira, Vera Cavalcanti de Araújo, Andresa Borges Soares

Clinical Pathology · 2019

DOI: 10.1177/2632010x19873384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pathology, 2019. Verfasst von Ana Amélia de Souza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, São Leopoldo Mandic Institute and Research Center, Campinas, Brazil. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA.

Schlagwörter

Stichwörter der Autor:innen

HER-2Pleomorphic adenomaestrogenprogesteronerecurrence

Autor:innen und Institutionen

  • Department of Oral Pathology, São Leopoldo Mandic Institute and Research Center, Campinas, Brazil.
  • Department of Pathology, School of Medicine, State University of Campinas (UNICAMP), Campinas, Brazil.

Zitieren

APA

de Souza, A. A., Altemani, A., de Araujo, N. S., Texeira, L. N., de Araújo, V. C., & Soares, A. B. (2019). Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma. Clinical Pathology. https://doi.org/10.1177/2632010x19873384

Vancouver

de Souza AA, Altemani A, de Araujo NS, Texeira LN, de Araújo VC, Soares AB. Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma. Clinical Pathology. 2019. doi:10.1177/2632010x19873384

BibTeX
@article{deSouza2019,
  author = {de Souza, Ana Amélia and Altemani, Albina and de Araujo, Ney Soares and Texeira, Lucas Novaes and de Araújo, Vera Cavalcanti and Soares, Andresa Borges},
  title = {Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma},
  journal = {Clinical Pathology},
  year = {2019},
  doi = {10.1177/2632010x19873384}
}
Kostenlos starten →